Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Neurology
  •  Signs and Symptoms-Clinical Findings
  •  Vascular Medicine
  •  Cancer Clinic
  •  Orthopedic Surgery
  •  Asthma
  •  Anesthesiology and Pain Medicine
  •  Geriatric Medicine

Abstract

Citation: Ann Clin Case Rep. 2021;6(1):1925.DOI: 10.25107/2474-1655.1925

Statistical Considerations for Gene Therapy Rare Disease Clinical Trials

Chenxuan Zang, Wei Zhang, Shein-Chung Chow

Department of Biostatistics and Bioinformatics, Duke University School of Medicine, USA Protech Pharma Services Corporation, USA

*Correspondance to: Chenxuan Zang 

 PDF  Full Text Case Report | Open Access

Abstract:

On December 18, 2017, the FDA approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy product developed for treating patients born with a kind of retinal disorder due to biallelic RPE65 gene mutation. Luxturna is a major medical advance since it is the first gene therapy to be granted approval by FDA that targets on a single gene. Approval of Luxturna may provide new prospects for curing various intractable and life-threatening rare diseases. As indicated by the former FDA Commissioner Scott Gottlieb, FDA can see a bright future of gene therapy, through which many dreaded, usually terminal medical problems may be solved, and now it is a critical time for the development of this novel form of treatment. As a result, FDA has been devoted to establishing an integrated, appropriate policy framework to encourage and administrate gene therapy research. FDA will also gradually promulgate a series of disease-specific guidance papers to demonstrate the clinical development and detailed approval process of investigational gene therapy products to discuss some critical and creative thinking that might be helpful to evaluate the efficacy of GT products and accelerate approval process. In this article, FDA guidance on clinical trial design issues for gene therapy development of rare diseases and some current innovative statistical considerations are reviewed. In addition, a case study of Luxturna, the first approved gene therapy for a rare disease is discussed.

Keywords:

Rare disease drug development; Demonstrating effectiveness or not in effectiveness; Real-world evidence; Therapeutic index

Cite the Article:

Zang C, Zhang W, Chow SC. Statistical Considerations for Gene Therapy Rare Disease Clinical Trials. Ann Clin Case Rep. 2021; 6: 1925..

Search Our Journal

Journal Indexed In

Articles in PubMed

Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Psoriasis Complicated with Acute Myocardial Infarction: A Case Report and Literature Review
 Abstract  PDF  Full Text
A New Method of SARS-CoV-2 Screening for Pregnant Women Based on Non-Invasive Prenatal Test
 Abstract  PDF  Full Text
View More...